Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial

Authors not listed

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1997

Abstract

The purpose of this study is to evaluate the safety and effectiveness of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease using a flexible dose design.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (1997). Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00253227
Vancouver
Anonymous. Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 1997.
BibTeX
@misc{anon1997Galant, title = {Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial}, author = {Anonymous}, journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.}, year = {1997}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings